吴丹丹医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 围孕期不良代谢因素暴露对母儿近远期安全性的影响

注册号:

Registration number:

ChiCTR2000034682 

最近更新日期:

Date of Last Refreshed on:

2020-07-16 14:34:33 

注册时间:

Date of Registration:

2020-07-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

吴丹丹医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 围孕期不良代谢因素暴露对母儿近远期安全性的影响

Public title:

Effect of adverse metabolic factors exposure during pregnancy on pregnancy outcomes and offspring safety

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围孕期不良代谢因素暴露对母儿近远期安全性的影响

Scientific title:

Effect of adverse metabolic factors exposure during pregnancy on pregnancy outcomes and offspring safety

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴丹丹 

研究负责人:

林仙华,吴丹丹 

Applicant:

Dandan Wu 

Study leader:

Xianhua Lin, Dandan Wu 

申请注册联系人电话:

Applicant telephone:

+86 021-64070434-30200

研究负责人电话:

Study leader's
telephone:

+86 021-64073897

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

woodendenny@163.com

研究负责人电子邮件:

Study leader's E-mail:

xl_1290@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

https://www.ipmch.com.cn

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

https://www.ipmch.com.cn

申请注册联系人通讯地址:

上海市徐汇区衡山路910号

研究负责人通讯地址:

上海市徐汇区衡山路910号

Applicant address:

910 Hengshan Road, Xuhui District, Shanghai, China

Study leader's address:

910 Hengshan Road, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属国际和平妇幼保健院

Applicant's institution:

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiaotong University, School of Medicine

研究负责人所在单位:

上海交通大学医学院附属国际和平妇幼保健院

Affiliation of the Leader:

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiaotong University, School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属国际和平妇幼保健院

Primary sponsor:

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiaotong University, School of Medicine

研究实施负责(组长)单位地址:

上海市徐汇区衡山路910号

Primary sponsor's address:

910 Hengshan Road, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属国际和平 妇幼保健院

具体地址:

徐汇区衡山路910号

Institution
hospital:

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiao Tong University, School of Medicine

Address:

910 Hengshan Road, Xuhui District

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

孕期代谢紊乱  

Target disease:

metablic disorder during pregnancy

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

研究围孕期不良代谢因素暴露对母儿近远期安全性的影响。  

Objectives of Study:

To investigate of the effect of adverse metabolic factors exposure during pregnancy on pregnancy outcomes and offspring safety.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 影响宫内发育、孕期母亲安全的严重内科合并症;
2. 已知恶性肿瘤、重大手术、外伤史;
3. 高脂血症家族史,孕前糖尿病、甲亢甲减;
4. 长期服用降糖/降脂/甲亢药物史;
5. 已知的严重胎儿畸形。

Exclusion criteria:

1. Severe medical complications which significantly harm fetal growth and maternal health during pregnancy;
2. Malignant tumor, major surgery or injury;
3. With history of major surgery, trauma or major organ disease;
4. Long term medicine taken history;
5. Known major fetal malformations.

研究实施时间:

Study execute time:

From 2020-08-01 00:00:00 To 2025-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-08-01 00:00:00 To 2021-07-31 00:00:00

干预措施:

Interventions:

组别:

暴露组

样本量:

2000

Group:

Exposed group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

对照组

样本量:

18000

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属国际和平 妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiaotong University, School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省台州医院 

单位级别:

三级甲等 

Institution
hospital:

Taizhou hospital of Zhejiang province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

松江区妇幼保健院 

单位级别:

二级甲等 

Institution
hospital:

Maternity and Child Health Hospital of Songjiang DistrictMaternity and Child Health Hospital of Songjiang DistrictMaternity and Child Health Hospital of Songjiang District

Level of the institution:

Secondary A

测量指标:

Outcomes:

指标中文名:

妊娠期糖尿病

指标类型:

主要指标

Outcome:

GDM

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

妊娠期高血压疾病

指标类型:

主要指标

Outcome:

HDP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早产

指标类型:

主要指标

Outcome:

premature delivery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胎盘早剥

指标类型:

主要指标

Outcome:

placental abruption

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胎儿出生体重

指标类型:

次要指标

Outcome:

birthweight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 50 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

项目完成半年后,需要原始数据的人员申请并通过项目委员会批准后将通过加密邮件方式传输给申请人员。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be transmitted to the applicant through encrypted mail after approval by the project committee.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用纸质问卷,由项目专人负责数据录入,所有数据将保存在RedCap网络云平台中。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection uses a paper questionnaire, and the project person is responsible for data entry. All data will be stored in the RedCap.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-07-14 23:49:29